KIDS vs. TNDM, LMAT, CNMD, TMDX, SLNO, CDRE, INMD, BLFS, RXST, and AORT
Should you be buying OrthoPediatrics stock or one of its competitors? The main competitors of OrthoPediatrics include Tandem Diabetes Care (TNDM), LeMaitre Vascular (LMAT), CONMED (CNMD), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Cadre (CDRE), InMode (INMD), BioLife Solutions (BLFS), RxSight (RXST), and Artivion (AORT). These companies are all part of the "medical equipment" industry.
OrthoPediatrics vs.
Tandem Diabetes Care (NASDAQ:TNDM) and OrthoPediatrics (NASDAQ:KIDS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.
69.1% of OrthoPediatrics shares are held by institutional investors. 2.2% of Tandem Diabetes Care shares are held by insiders. Comparatively, 31.8% of OrthoPediatrics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Tandem Diabetes Care presently has a consensus target price of $53.81, suggesting a potential upside of 45.20%. OrthoPediatrics has a consensus target price of $39.00, suggesting a potential upside of 62.50%. Given OrthoPediatrics' higher possible upside, analysts plainly believe OrthoPediatrics is more favorable than Tandem Diabetes Care.
Tandem Diabetes Care has a net margin of -14.84% compared to OrthoPediatrics' net margin of -15.00%. OrthoPediatrics' return on equity of -5.78% beat Tandem Diabetes Care's return on equity.
Tandem Diabetes Care received 273 more outperform votes than OrthoPediatrics when rated by MarketBeat users. However, 64.26% of users gave OrthoPediatrics an outperform vote while only 61.28% of users gave Tandem Diabetes Care an outperform vote.
OrthoPediatrics has lower revenue, but higher earnings than Tandem Diabetes Care. OrthoPediatrics is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.
In the previous week, Tandem Diabetes Care had 1 more articles in the media than OrthoPediatrics. MarketBeat recorded 4 mentions for Tandem Diabetes Care and 3 mentions for OrthoPediatrics. Tandem Diabetes Care's average media sentiment score of 1.40 beat OrthoPediatrics' score of 0.06 indicating that Tandem Diabetes Care is being referred to more favorably in the media.
Tandem Diabetes Care has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.
Summary
Tandem Diabetes Care and OrthoPediatrics tied by winning 9 of the 18 factors compared between the two stocks.
Get OrthoPediatrics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KIDS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OrthoPediatrics Competitors List
Related Companies and Tools
This page (NASDAQ:KIDS) was last updated on 2/1/2025 by MarketBeat.com Staff
